UCP1 and metabolic disease: Remarkably, by the induction of Uncoupling Protein 1, tofacitinib induced the phenomenon of adipocyte browning and/or the emergence of brown-like adipocytes in white adipose depots with consequent relevant metabolic benefits in the treatment of the metabolic diseases [23].